Evaluation of Three Rhenium-188 Candidates for Intravascular Radiation Therapy with Liquid-filled Balloons to Prevent Restenosis

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 2000 Mar 4

PMID 10698233

Citations 1

Authors

W Y Lin

S C Tsai

B T Hsieh

T W Lee

G Ting

S J Wang

Affiliations

Soon will be listed here.

Abstract

Background: Intravascular brachytherapy is an effective method for inhibiting coronary restenosis after percutaneous transluminal coronary angioplasty. A new concept for preventing restenosis is the use of a liquid-filled balloon containing a beta-ray-emitting radioisotope. Generator-produced rhenium-188 (Re-188) is a good candidate for intravascular brachytherapy. However, in the unlikely event of balloon rupture, release of Re-188 perrhenate may cause a high radiation dose to the thyroid and stomach. In this study, we compared the biodistributions of three Re-188 preparations (Re-188 perrhenate, Re-188 pentetic acid [DTPA], and Re-188 MAG3) to assess the radiation dose to organs in a rat model that mimicked balloon rupture.

Methods And Results: After injection of Re-188 preparations intravenously, rats were killed at 10 minutes, 30 minutes, 60 minutes, 2 hours, and 6 hours (n = 5/group). Tissue concentrations were calculated and expressed as percent injected dose per gram or per milliliter. In addition, urine excretion and thyroid gland uptake were evaluated in rats (n = 5/group) with a gamma camera after administration of 37 MBq (1 mCi) of each agent. Our data showed all 3 agents were excreted primarily via urine. In the Re-188 MAG3 group, 82% was excreted within 1 hour, but in the Re-188 perrhenate group, only 28% was excreted. The biodistribution data for these agents revealed that radioactivity levels in the stomach and the thyroid gland were high in the perrhenate group but low in the Re-188 DTPA and Re-188 MAG3 groups. The concentration levels in other tissues including lung, liver, testis, muscle, and blood were low throughout this study for all 3 agents. The thyroid radiation values were 0.163, 0.0167, and 0.00728 mGy/MBq for Re-188 perrhenate, Re-188 DTPA, and Re-188 MAG3, respectively. The stomach radiation values were 0.127 mGy/MBq for Re-188 perrhenate, 0.013 mGy/MBq for Re-188 DTPA, and 0.0104 mGy/MBq for Re-188 MAG3.

Conclusions: In the event of balloon rupture, the release of Re-188 MAG3 or Re-188 DTPA results in lower radiation doses than release of Re-188 perrhenate, especially to the thyroid gland and the stomach.

Citing Articles

Dosimetry in leakage of (188)Re-DTPA during intracoronary balloon brachytherapy.

Paeng J, Lee D, Kang W, Yang H, Chung J, Jeong J Eur J Nucl Med Mol Imaging. 2003; 30(9):1263-5.

PMID: 12811423 DOI: 10.1007/s00259-003-1235-9.

References

Knapp Jr F, Beets A, Guhlke S, Zamora P, Bender H, Palmedo H . Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 1997; 17(3B):1783-95. View

Mayberg M, Luo Z, London S, Gajdusek C, Rasey J . Radiation inhibition of intimal hyperplasia after arterial injury. Radiat Res. 1995; 142(2):212-20. View

Popma J, Califf R, Topol E . Clinical trials of restenosis after coronary angioplasty. Circulation. 1991; 84(3):1426-36. DOI: 10.1161/01.cir.84.3.1426. View

Favus M, Schneider A, Stachura M, Arnold J, Ryo U, Pinsky S . Thyroid cancer occurring as a late consequence of head-and-neck irradiation. Evaluation of 1056 patients. N Engl J Med. 1976; 294(19):1019-25. DOI: 10.1056/NEJM197605062941901. View

Fischell T, Kharma B, Fischell D, Loges P, Coffey 2nd C, Duggan D . Low-dose, beta-particle emission from 'stent' wire results in complete, localized inhibition of smooth muscle cell proliferation. Circulation. 1994; 90(6):2956-63. DOI: 10.1161/01.cir.90.6.2956. View

PRINCE J, Bancroft S, Dukstein W . Pharmacokinetics of pertechnetate administered after pretreatment with 400 mg of potassium perchlorate: concise communication. J Nucl Med. 1980; 21(8):763-6. View

Amols H, Zaider M, Weinberger J, Ennis R, Schiff P, Reinstein L . Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys. 1996; 36(4):913-21. DOI: 10.1016/s0360-3016(96)00301-x. View

Miller R, Martenson J, Sargent D, Kahn M, Krook J . Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998; 41(3):593-8. DOI: 10.1016/s0360-3016(98)00084-4. View

Teirstein P, Massullo V, Jani S, Popma J, Mintz G, Russo R . Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997; 336(24):1697-703. DOI: 10.1056/NEJM199706123362402. View

10.

Wang S, Lin W, Chen M, Hsieh B, Shen L, Tsai Z . Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med. 1996; 23(1):13-7. DOI: 10.1007/BF01736984. View

11.

Schwartz R, Koval T, Edwards W, Camrud A, Bailey K, Browne K . Effect of external beam irradiation on neointimal hyperplasia after experimental coronary artery injury. J Am Coll Cardiol. 1992; 19(5):1106-13. DOI: 10.1016/0735-1097(92)90303-5. View

12.

CLOUTIER R, Smith S, Watson E, SNYDER W, Warner G . Dose to the fetus from radionuclides in the bladder. Health Phys. 1973; 25(2):147-61. DOI: 10.1097/00004032-197308000-00009. View

13.

Amols H, Reinstein L, Weinberger J . Dosimetry of a radioactive coronary balloon dilatation catheter for treatment of neointimal hyperplasia. Med Phys. 1996; 23(10):1783-8. DOI: 10.1118/1.597761. View

14.

Madrazo A, Schwarz G, Churg J . Radiation nephritis: a review. J Urol. 1975; 114(6):822-7. DOI: 10.1016/s0022-5347(17)67152-0. View

15.

Oldendorf W, Sisson W, Lisaka Y . Compartmental redistribution of 99mTc-pertechnetate in the presence of perchlorate ion and its relation to plasma protein binding. J Nucl Med. 1970; 11(2):85-8. View

16.

Wiedermann J, Marboe C, Amols H, Schwartz A, Weinberger J . Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: persistent benefit at 6-month follow-up. J Am Coll Cardiol. 1995; 25(6):1451-6. DOI: 10.1016/0735-1097(95)00010-2. View

17.

Deutsch E, Libson K, Vanderheyden J, Ketring A, Maxon H . The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B. 1986; 13(4):465-77. DOI: 10.1016/0883-2897(86)90027-9. View

18.

Stabin M . MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996; 37(3):538-46. View

19.

Serruys P, Luijten H, Beatt K, Geuskens R, de Feyter P, van den Brand M . Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988; 77(2):361-71. DOI: 10.1161/01.cir.77.2.361. View

20.

Prestwich W, Kennett T, Kus F . The dose distribution produced by a 32P-coated stent. Med Phys. 1995; 22(3):313-20. DOI: 10.1118/1.597455. View